Sanguinaria oral care safety
This article was originally published in The Rose Sheet
Executive Summary
Sanguinaria extract in oral hygiene products "may not be safe or even desirable to use," Boston University Oral and Maxillofacial Pathology Professor Sadru Kabani states in July 21 comments to FDA regarding advance notice of proposed rulemaking on OTC antigingivitis/antiplaque products. Kabani bases comments on observations made clinically and microscopically since 1995, including experience with 15-20 patients who have developed oral leukoplakia and notes, "current research suggests that sanguinaria may have a possible role in the pathogenesis of these oral changes." Research on the ingredient up to the end of 1998 on which FDA based its recommendations "appeared in non-peer reviewed journals based on studies for a short duration of time," Kabani adds. Sanguinaria was included as Category I for safety in the ANPR released in May (1"The Rose Sheet" June 2, 2003, p. 3)...
You may also be interested in...
Antigingivitis/Antiplaque Combination With Other Actives Excluded In ANPR
FDA's advance notice of proposed rulemaking on OTC antigingivitis/antiplaque products excludes the combination of antigingivitis/antiplaque ingredients with other oral health care ingredients. The 1notice was published in the May 29 Federal Register
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.